Skip to main content

Site notifications

(Approval lapsed) EPIRUBICIN ACCORD epirubicin hydrochloride 200mg/100mL Solution for Injection or Infusion (UK)

Section 19A approved medicine
(Approval lapsed) EPIRUBICIN ACCORD epirubicin hydrochloride 200mg/100mL Solution for Injection or Infusion (UK)
Section 19A approval holder
Accord Healthcare Pty Ltd ABN 49 110 502 513
Phone
1800 222 673
Approved until
Status
Expired
Medicines in short supply/unavailable
EPIRUBICIN ACCORD epirubicin hydrochloride 200mg/100mL concentrated injection vial - ARTG 227997
PHARMORUBICIN epirubicin hydrochloride 200mg/100mL injection vial - ARTG 49746
EPIRUBICIN AN epirubicin hydrochloride 200 mg/100 mL concentrated injection vial - ARTG 146599
Indication(s)
  • Epirubicin hydrochloride has produced responses in a wide spectrum of neoplastic diseases. Epirubicin Hydrochloride injection is indicated for the treatment of breast cancer, gastric cancer, ovarian cancer, small cell lung cancer, lymphoma (non-Hodgkin's lymphoma), advanced/ metastatic soft tissue sarcoma and superficial bladder cancer (Tis, Ta).
  • In bladder cancer, Epirubicin Hydrochloride injection is also indicated in the prophylaxis of recurrence after transurethral resection of stage T1 papillary cancers and stage Ta multifocal papillary cancers (grade 2 and 3).
Published

Help us improve the Therapeutic Goods Administration site